0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Cutting Edge: Challenges in Medical and Surgical Therapies |

Angiosarcoma of the Scalp Successfully Treated With a Single Therapy of Sorafenib

Sachiko Ono, MD; Miki Tanioka, MD, PhD; Akihiko Fujisawa, MD, PhD; Hideaki Tanizaki, MD, PhD; Yoshiki Miyachi, MD, PhD; Yumi Matsumura, MD, PhD
Arch Dermatol. 2012;148(6):683-685. doi:10.1001/archdermatol.2011.2819.
Text Size: A A A
Published online

Extract

Angiosarcoma (AS) of the scalp is a rare and aggressive neoplasm with one of the worst prognoses among malignant skin tumors. The overall 5-year survival rate is less than 30%.1 Specific treatment guidelines are absent, and treatment options include surgical excision, radiation therapy, chemotherapy (CT), and biological therapy such as recombinant interleukin 2 (rIL-2). Surgical excision with negative margins combined with CT is the most successful strategy for improving the prospect for survival.2,3

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Clinical photographs of patient 1. Before (A) and after sorafenib therapy, at week 8 (B).

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Clinical photographs of patient 2 before (A) and after sorafenib therapy, at week 12 (B).

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

583 Views
10 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();